WO2018062751A1 - Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu - Google Patents

Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu Download PDF

Info

Publication number
WO2018062751A1
WO2018062751A1 PCT/KR2017/010252 KR2017010252W WO2018062751A1 WO 2018062751 A1 WO2018062751 A1 WO 2018062751A1 KR 2017010252 W KR2017010252 W KR 2017010252W WO 2018062751 A1 WO2018062751 A1 WO 2018062751A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lactobacillus plantarum
hair
scalp
eluate
Prior art date
Application number
PCT/KR2017/010252
Other languages
English (en)
Korean (ko)
Inventor
이용희
명길선
나용주
김용진
유세진
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to CN201780073315.0A priority Critical patent/CN110494125B/zh
Publication of WO2018062751A1 publication Critical patent/WO2018062751A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • This specification relates to a composition for hair or scalp comprising an eluate of Lactobacillus plantarum.
  • the microbial resource is a highly useful material that utilizes the unique characteristics of microorganisms adapted in various environments as a sustainable resource in terms of reproduction.
  • lactic acid bacteria are used as probiotics in the food field as materials that can be used without risk to the human body.
  • the problem to be solved by the present invention is to provide a composition having excellent hair growth and hair loss prevention efficacy.
  • the problem to be solved by the present invention is to provide a composition having excellent hair growth and hair loss prevention efficacy without human toxicity or irritation.
  • the problem to be solved by the present invention is to provide a composition having excellent hair growth enhancement and hair loss prevention effect using a component derived from nature.
  • the problem to be solved by the present invention is to provide a composition excellent in promoting the proliferation of hair follicle dermal papilla cells, and suppresses the death thereof.
  • the problem to be solved by the present invention is to provide a composition excellent in promoting the proliferation of appearance myocytes, and suppresses the death.
  • the present invention relates to a hair or scalp composition
  • a hair or scalp composition comprising an lysate of Lactobacillus plantarum as an active ingredient.
  • the present invention (a) Lactobacillus plantarum ( Lactobacillus plantarum ) is cultured,
  • (c) a hair comprising the eluate of Lactobacillus plantarum, which is eluted by heating the Lactobacillus plantarum obtained in (b) at 80 ° C to 120 ° C for 10 to 30 minutes, or It relates to a method for preparing a scalp composition.
  • the present invention can provide a composition excellent in hair growth promotion and hair loss prevention efficacy.
  • the present invention can provide a composition having excellent hair growth enhancement and hair loss prevention efficacy without human toxicity or irritation.
  • the present invention can provide excellent hair growth promotion and hair loss prevention efficacy by using ingredients derived from nature.
  • the present invention can provide a composition excellent in promoting the proliferation of hair follicle dermal papilla cells and inhibiting the death thereof.
  • the present invention can provide an excellent composition for promoting the proliferation of appearance myocytes and inhibiting their death.
  • 1 is a graph showing the hair follicle dermal papilla cell growth promoting effect of Lactobacillus plantarum.
  • Figure 2 is a result graph showing the effect of Lactobacillus plantarum promotes the appearance of myocyte root proliferation.
  • Figure 3 is a result graph showing the effect of Lactobacillus plantarum inhibits the appearance of myocytes.
  • Figure 4 is a fluorescence micrograph showing the effect of Lactobacillus plantarum inhibiting appearance myocytes cell death.
  • compositions for hair or scalp comprising an lysate of Lactobacillus plantarum as an active ingredient.
  • the Lactobacillus plantarum may be derived from a tea tree. In one embodiment, the Lactobacillus plantarum is Camellisa sinensis ) may be isolated from the leaves.
  • the Lactobacillus plantarum may be an APsulloc 331266 (Accession No. KCCM11181P) strain.
  • the strain may be identified and isolated from the tea leaves, it may exhibit a remarkably excellent hair growth and hair loss prevention effect among the various Lactobacillus plantarum strains isolated and identified from the tea leaves.
  • the eluate may be a heated eluate obtained by heating and eluting cells of Lactobacillus plantarum.
  • the heating is 80 ° C or higher, 81 ° C or higher, 82 ° C or higher, 83 ° C or higher, 84 ° C or higher, 85 ° C or higher, 86 ° C or higher, 87 ° C or higher, 88 ° C or higher, 89 ° C or higher, 90 ° C or higher, 91 degrees C or more, 92 degrees C or more, 93 degrees C or more, 94 degrees C or more, 95 degrees C or more, 96 degrees C or more, 97 degrees C or more, 98 degrees C or more, 99 degrees C or more, or 100 degrees C or more, 120 degrees C or less, 119 degrees C or less, 118 Or less, 117 or less, 116 or less, 115 or less, 114 or less, 113 or less, 112 or less, 111 or less, 110 or less, 109 or less
  • the heating may be at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, or at least 15 minutes. 30 minutes or less, 29 minutes or less, 28 minutes or less, 27 minutes or less, 26 minutes or less, 25 minutes or less, 24 minutes or less, 23 minutes or less, 22 minutes or less, 21 minutes or less, 20 minutes or less, 19 minutes or less, 18 minutes or less, 16 minutes or less, or 15 minutes or less.
  • the heated eluate is a natural ingredient, there is little irritation or toxicity when applied to the human body, hair growth enhancement and hair loss prevention effect can be remarkably excellent.
  • the eluate is (a) Lactobacillus plantarum culture ( Lactobacillus plantarum ),
  • (c) may be prepared by eluting the Lactobacillus plantarum obtained in (b) by heating at 80 to 120 °C for 10 to 30 minutes.
  • composition according to an embodiment of the present invention is excellent in safety because it is almost no irritation or toxicity when applied to the human body as a natural component. In addition, it promotes proliferation of hair follicle dermal papilla cells and hair follicle myocytes, inhibits the death of the hair follicles, and can exhibit remarkably excellent hair growth promoting effect and hair loss prevention effect.
  • the composition may be a topical skin composition.
  • the external preparation composition may be, for example, a cosmetic composition.
  • compositions according to one embodiment of the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base.
  • a cosmetically or dermatologically acceptable medium or base for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and non-obtained by dispersing an oil phase in solution, gels, solids, pasty anhydrous products, aqueous phases.
  • It may be provided in the form of an ionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
  • These compositions can be prepared according to conventional methods in the art.
  • composition according to an embodiment of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
  • the cosmetic composition may include the Lactobacillus plantarum eluate 0.1% to 20% by weight relative to the total weight of the composition.
  • the composition may be used as a scalp or hair composition. Therefore, the composition may be used in combination with the scalp and hair, such as shampoos, rinses, scalp treatments, hair treatments, scalp hair treatments, hair loss treatments, damaged hair treatments, and leave-in. ) Scalp or hair, scalp and hair combination products, such as conditioner, wash-off conditioner or hair essence.
  • composition of each of these formulations may contain various components formulated into conventional scalp or hair compositions according to the various formulations described above or as appropriate for the end purpose, and the types and amounts of these components can be easily selected by those skilled in the art. .
  • the composition may comprise 0.1 to 20% by weight of the Lactobacillus plantarum eluate relative to the total weight of the composition.
  • the composition according to the embodiment of the present invention is a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, and an ionic type.
  • nonionic emulsifiers fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other commonly used in cosmetics
  • the adjuvant may be introduced in amounts generally used in the cosmetic or dermatological arts, for example from 0.001% to 5% by weight, for example from 0.001 to 3% by weight relative to the total weight of the composition.
  • the composition may be a pharmaceutical composition.
  • the pharmaceutical composition according to the present disclosure may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, or the like. Or lactose, gelatin, or the like is mixed.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • compositions herein may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
  • the salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzene sulfonic acid, toluene sulfonic acid, naphthalene sulfonic acid and the like can be used.
  • composition of the present disclosure may be parenterally or orally administered as desired, and may be administered in one to several times so as to be administered in an amount of 0.1 to 500 mg, preferably 1 to 100 mg per kg of body weight per day. have.
  • the dosage for a particular patient may vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of the disease, and the like.
  • the pharmaceutical composition according to the present specification may be a powder, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, oral formulations such as aerosols, ointments, creams, etc. And sterile injectable solutions and the like, and may be formulated in any form suitable for pharmaceutical preparations.
  • the tea leaves were washed twice with distilled water to remove foreign substances, the water of the washed tea leaves were shaken off and mixed with the salt corresponding to 8% of the weight of the tea leaves and left at room temperature for 3 hours.
  • the salted tea leaves were mixed with 1000 ml of a 1% fructo oligosaccharide solution and incubated in a 32 ° C. incubator for 3 days. After 3 days, the pH of the culture medium was checked to be lower than 5, and when the pH was lower than 5, it was taken and incubated in Difco Lactobacilli MRS Agar® medium.
  • Lactobacillus plantarum APsulloc 331266 (Accession Number: KCCM11181P) was isolated from the tea leaves in the same manner as above.
  • the isolated Lactobacillus plantarum APsulloc 331266 was stored in Cryotubes at 10% by weight in skim milk, inoculated in medium (MRS Broth), and incubated in a 37 ° C. environment for 24 hours.
  • the bacteria concentration in the liquid medium was 5 X 10 8 ⁇ 1 X 10 9 CFU / ml, at 4 ° C, the feeder cells were harvested by centrifugation at 4000 rpm and washed with PBS (phosphate buffered saline). The washed cells were re-dispersed in PBS at a concentration of 5 ⁇ 10 8 to 1 ⁇ 10 9 CFU / mL and heated at 100 ° C. for 10 minutes to obtain an eluate.
  • PBS phosphate buffered saline
  • Test 1 Proliferative effect of hair follicle papilla cells (MTT assay)
  • the eluate prepared in Preparation Example 1 was used to confirm the proliferation effect in human hair follicle papilla cells (hDPCs; human Dermal papilla Cell).
  • the dermal papilla cells were isolated from the scalp scalp tissue and cultured for 14 days in a culture dish coated with collagen type I.
  • Culture medium containing DMEM (Dulbecco's modified eagles medium; HyClone GE Healthcare) with antibiotic (1%), fungizone (0.1%), 20% FBS, 5% CO 2, for 72 hours at 37 ° C
  • the medium was replaced with DMEM medium added with 10% FBS, and when the cells grew more than 90% of the dish, the cells were collected using 0.25% trypsin / 10mM EDTA (Welgene) and 10% FBS Incubated for 72 hours (until the cells grew more than 90% of the dish) in the DMEM medium, 5% CO 2, 37 °C added to provide the experiment.
  • HDPCs were inoculated in 2000 wells / well in 96 well plates and incubated at 5% CO 2, 37 ° C for 24 hours. 10% by volume of the eluate prepared in Preparation Example 1 was incubated at 37% for 5% CO 2 for 72 hours. A control group was used as a control group, and 5% FBS was treated with the same as the eluate as a positive control group.
  • MTT solution (Sigma, 70 ⁇ g / well) was added to each well of the 96 well plate and incubated at 5% CO 2, 37 ° C. for 3 hours. Thereafter, formazan was dissolved in DMSO and absorbance was measured at 570 nm using a microplate reader. The relative cell proliferation rate is shown in FIG. 1 with a control value of 100 in the measured result.
  • the superficial myoblasts were isolated from the scalp scalp tissue and cultured for 14 days in a culture dish coated with collagen type I.
  • DMEM Disulbecco's modified eagles medium
  • FBS 5% CO 2
  • MTT solution (Sigma, 70 ⁇ g / well) was added to each well of the 96 well plate and incubated at 5% CO 2, 37 ° C. for 3 hours. Thereafter, formazan was dissolved in DMSO and absorbance was measured at 570 nm using a microplate reader. The relative cell proliferation rate is shown in FIG. 2 with the control value as 100 in the measured result.
  • Appearance and myoblasts isolated and cultured as in Test Example 2 were inoculated at 20000 / well in a 96 well plate and 8 chamber slide incubated for 24 hours at 5% CO 2, 37 °C conditions. After 24 hours of starvation, the cells were treated with DKK 50ng / ml and DKK 50ng / ml + 10% by volume of the eluate prepared in Preparation Example 1, respectively.
  • the growth factor (EpiLife S-012-5, invitrogen) was added to the E. coli culture medium (EPILIFE MEPI500CA, invitrogen) in the same amount as the eluate.
  • MTT solution (Sigma, 70 ⁇ g / well) was added to each well of the 96 well plate treated with the test material and incubated at 5% CO 2, 37 ° C. for 3 hours. Thereafter, formazan was dissolved in DMSO and absorbance was measured at 570 nm using a microplate reader. The results are shown in FIG. 3 as relative cell proliferation rate (***) with a negative control value of 100 and relative cell proliferation rate ( ⁇ ) with a value of 100 treated with DKK-1 only.
  • the 8 chamber slide treated with the test substance was fixed for 24 hours using 4% paraformaldehyde (Paraformaldehyde), washed, and treated with triton-X100 0.05% (in PBS). After the reaction using a TUNEL reaction mixture (TUNEL reaction mixture, Roche kit) was washed, stained with DAPI (4 ', 6-diamidino-2-phenylindole) and observed under a fluorescence microscope. Fluorescence micrographs of the cells are shown in FIG. 4.
  • Injections were prepared by conventional methods according to the compositions set forth in the table below.
  • composition shown in the following table was prepared in the conventional method for the flexible cosmetic.
  • a hair lotion is prepared according to a conventional method with the composition described in the table below.
  • a shampoo composition was prepared according to a conventional method with the compositions described in the table below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition contenant un lysat de Lactobacillus plantarum en tant que principe actif pour les cheveux ou le cuir chevelu. La composition peut présenter d'excellents effets d'activation de la pousse des cheveux et de prévention de la perte de cheveux.
PCT/KR2017/010252 2016-09-27 2017-09-19 Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu WO2018062751A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780073315.0A CN110494125B (zh) 2016-09-27 2017-09-19 包含植物乳杆菌的溶菌液的毛发或头皮用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160124175A KR102610933B1 (ko) 2016-09-27 2016-09-27 락토바실러스 플란타룸의 용출물을 포함하는 모발 또는 두피용 조성물
KR10-2016-0124175 2016-09-27

Publications (1)

Publication Number Publication Date
WO2018062751A1 true WO2018062751A1 (fr) 2018-04-05

Family

ID=61762881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010252 WO2018062751A1 (fr) 2016-09-27 2017-09-19 Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu

Country Status (4)

Country Link
KR (1) KR102610933B1 (fr)
CN (1) CN110494125B (fr)
TW (1) TWI796304B (fr)
WO (1) WO2018062751A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115501165A (zh) * 2022-09-22 2022-12-23 深圳市兰亭科技股份有限公司 一种用于头皮护理的组合物及其制备方法与应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200064594A (ko) * 2018-11-29 2020-06-08 (주)아모레퍼시픽 녹차 유래 유산균을 포함하는 미세먼지에 의한 탈모 케어용 조성물
KR102350733B1 (ko) * 2020-04-29 2022-01-14 주식회사 코스메카코리아 탈모방지 또는 발모촉진용 조성물
KR20230088343A (ko) * 2020-10-21 2023-06-19 닛신 쇼꾸힝 홀딩스 가부시끼가이샤 유산균을 함유하는 발모·육모 효과를 갖는 음식품, 화장품, 의약부외품 또는 의약품
KR102429565B1 (ko) 2021-09-13 2022-08-04 연세대학교 원주산학협력단 락토바실러스 플란타럼 큐원을 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물
CN117050923B (zh) * 2023-10-13 2023-12-08 山东福瑞达生物股份有限公司 一株鼠李糖乳杆菌lr06及其在雪绒花发酵中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226892A1 (en) * 2009-03-04 2010-09-09 L'oreal Use of probiotic microorganisms to limit skin irritation
KR20130000001A (ko) * 2011-06-10 2013-01-02 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
KR20150072327A (ko) * 2013-12-18 2015-06-29 (주)제니트리 모유두세포 및 모모세포의 활성화능을 갖는 펩톤발효물을 포함하는 탈모방지 또는 발모촉진용 화장료 조성물, 및 이의 제형
KR101615314B1 (ko) * 2015-05-29 2016-05-13 ㈜새롬바이오 약재의 발효 추출물을 포함하는 탈모 방지 및 발모 촉진용 조성물
US20160250141A1 (en) * 2012-03-27 2016-09-01 L'oreal Use of a lysate of a culture of a bacterium of the vitreoscilla sp. genus for preventing and/or treating hyperseborrhoeic conditions of the scalp

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647694B1 (fr) * 2010-11-04 2017-12-27 Cell Biotech Co., Ltd. Biomasse morte de lactobacillus pour une utilisation antimicrobienne, et son procédé de production
WO2012169842A2 (fr) * 2011-06-10 2012-12-13 (주)아모레퍼시픽 Lactobacillus plantarum inédit isolé à partir de feuilles de camellia sinensis
KR101998210B1 (ko) 2012-10-31 2019-07-10 (주)아모레퍼시픽 녹차 유산균을 포함하는 피부 각질 제거용 조성물
JP6209153B2 (ja) * 2014-10-20 2017-10-04 イシズム株式会社 粉末配合物
CN105147589B (zh) * 2015-10-10 2017-10-31 林彤 一种去头屑组合物及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226892A1 (en) * 2009-03-04 2010-09-09 L'oreal Use of probiotic microorganisms to limit skin irritation
KR20130000001A (ko) * 2011-06-10 2013-01-02 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
US20160250141A1 (en) * 2012-03-27 2016-09-01 L'oreal Use of a lysate of a culture of a bacterium of the vitreoscilla sp. genus for preventing and/or treating hyperseborrhoeic conditions of the scalp
KR20150072327A (ko) * 2013-12-18 2015-06-29 (주)제니트리 모유두세포 및 모모세포의 활성화능을 갖는 펩톤발효물을 포함하는 탈모방지 또는 발모촉진용 화장료 조성물, 및 이의 제형
KR101615314B1 (ko) * 2015-05-29 2016-05-13 ㈜새롬바이오 약재의 발효 추출물을 포함하는 탈모 방지 및 발모 촉진용 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115501165A (zh) * 2022-09-22 2022-12-23 深圳市兰亭科技股份有限公司 一种用于头皮护理的组合物及其制备方法与应用
CN115501165B (zh) * 2022-09-22 2024-06-11 深圳市兰亭科技股份有限公司 一种用于头皮护理的组合物及其制备方法与应用

Also Published As

Publication number Publication date
CN110494125B (zh) 2022-09-13
CN110494125A (zh) 2019-11-22
KR20180034085A (ko) 2018-04-04
TW201813651A (zh) 2018-04-16
KR102610933B1 (ko) 2023-12-08
TWI796304B (zh) 2023-03-21

Similar Documents

Publication Publication Date Title
WO2018062751A1 (fr) Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu
WO2019004673A2 (fr) Composition anti-âge comprenant une vésicule extracellulaire dérivée de bactéries lactiques
WO2020096156A1 (fr) Nouvelle souche de lactobacillus gasseri skb1102 ou composition cosmétique la contenant ayant une fonction anti-pollution
WO2014069874A1 (fr) Composition permettant d'éliminer des substances kératiniques de la peau comprenant des lactobacillus de thé vert
WO2018139898A1 (fr) Composition destinée à renforcer l'immunité, contenant des polysaccharides de baie de ginseng
WO2018056600A1 (fr) Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté
WO2018084528A1 (fr) Composition antioxydante et d'amélioration de la peau
WO2021125488A1 (fr) Composition de lipolyse utilisant des nanoparticules génératrices de gaz modifiées en surface
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2024136126A1 (fr) Composition cosmétique contenant un extrait de fermentation de houttuynia cordata
WO2020218888A1 (fr) Composition cosmétique pour le blanchiment de la peau contenant de nouvelles lactobacillus rhamnosus lm1011 en tant que principe actif
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2024143881A1 (fr) Composition cosmétique contenant un extrait de feuille de carotte fermenté
WO2014077621A1 (fr) Composition pour la prévention de la chute des cheveux et l'accélération de la croissance des cheveux
WO2019225786A1 (fr) Composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif
KR102422611B1 (ko) 신규한 바실러스 벨레젠시스 균주 또는 이로부터 분리된 화합물 및 이의 용도
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2017138788A1 (fr) Composition anti-inflammatoire et anti-bactérienne contenant, comme principes actifs, un peptide dérivé d'un extrait de chungkukjang et un extrait naturel ou un produit de fermentation, et composition cosmétique destinée à prévenir ou à atténuer des dermopathies immunitaires contenant celle-ci
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
KR102610934B1 (ko) 락토바실러스 사케이의 용출물을 포함하는 모발 또는 두피용 조성물
WO2019172554A1 (fr) Composition cosmétique de blanchiment de la peau contenant une solution de mélange de cultures de lactobacilles
WO2019172666A1 (fr) Nouveau peptide antimicrobien dérivé du peptide ll37 et utilisation associée
WO2023128426A1 (fr) Composition cosmétique comprenant un extrait d'aiguille de pin fermenté
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2021182895A1 (fr) Composition cosmétique pour favoriser la présence de bactéries bénéfiques pour la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17856637

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17856637

Country of ref document: EP

Kind code of ref document: A1